Glucocorticoid therapy as a significant risk factor for osteoporosis and fractures in an Italian postmenopausal population

References

• NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785–95
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation. Physician's guide to prevention and treatment of osteoporosis; 1999, Updated January 2003. Available at: http://www.nof.org/ [last accessed 18 Jul 2005]
   Google Scholar
• Hodgson SF, Watts NB, Bilezikian JP, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract 2003;9:544–64. [Erratum, Endocr Pract 2004;10:90.]
   PubMedGoogle Scholar
• Office of the Surgeon General. Bone health and osteoporosis: a report of the Surgeon General. Rockville, MD: Department of Health and Human Services; 2004:436
   Google Scholar
• Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. Trend Endocrinol Metab 2006;7:144–9
   Google Scholar
• Canalis E, Bilezikian JP, Angeli A, Giustina A. Perspectives on glucocorticoid-induced osteoporosis. Bone 2004;34:593–8
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis. Osteoporos Int 2002;13:777–87
   PubMed Web of Science ®Google Scholar
• Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and risk pf hip and vertebral fractures among older women. Study of osteoporotic Fractures Research Group. N Engl J Med 1998;339:733–8
   PubMed Web of Science ®Google Scholar
• Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology ad hoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum 2001;44:1496–503
   PubMed Web of Science ®Google Scholar
• Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med 1999;159:941–55
   PubMed Web of Science ®Google Scholar
• van Staa TP, Leufkens HG, Cooper C. Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 2001;16:581–8
   PubMed Web of Science ®Google Scholar
• Kanis JA. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. WHO Study Group. Osteoporos Int 1994;4:368–81
   PubMed Web of Science ®Google Scholar
• Manelli F, Giustina A. Glucocorticoid-induced osteoporosis. Trends Endocrinol Metab 2000;11:79–85
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993–1000
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A. Glucocorticoid-induced osteoporosis: summary of a workshop. J Clin Endocrinol Metab 2001;86:5681–5
   PubMed Web of Science ®Google Scholar
• Van Staa TP, Leufkens HG, Abenhaim L, et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39:1383–9
   PubMed Web of Science ®Google Scholar
• Riggs BL, Khosla S, Melton LJ. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. Bone Miner Res 1998;13:763–73
   PubMed Web of Science ®Google Scholar
• Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids: potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274–82
   PubMed Web of Science ®Google Scholar
• Jia D, O’Brien CA, Stewart SA, et al. Glucocorticoids act directly on osteoclasts to increase their life span and reduce bone density. Endocrinology 2006;147:5592–9
   PubMed Web of Science ®Google Scholar
• Khosla S. Update on estrogens and the skeleton. J Clin Endocrinol Metab 2010;95:3569–77
   PubMed Web of Science ®Google Scholar
• Angeli A, Guglielmi G, Dovio A, et al. High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study. Bone 2006;39:253–9
   PubMed Web of Science ®Google Scholar
• Massafra U, Migliaccio S, Bancheri C, et al. Approach in glucocorticoid induced osteoporosis (GIO) prevention: results from the italian multi center observational EGEO study. J Endocrinol Invest 2013;36:92–6
   PubMed Web of Science ®Google Scholar
• Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010: recommendations for prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 2010;62:1515–26
   PubMed Web of Science ®Google Scholar
• Hansen KE, Wilson A, Zapalowsky C, et al. Uncertainties in the prevention and treatment of glucocorticoid-induced osteoporosis. J Bone Miner Res 2001;26:1989–96
   Google Scholar
• Management of osteoporosis in postmenopausal women: 2010 position statement of the Nord American Menopause Society. Menopause 2010;17:25–54
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Pines A; International Menopause Society Writing Group, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climateric 2011;14:302–20
   PubMed Web of Science ®Google Scholar
• Frax WHO Fracture Risk Assessment Tool. Available from: www.shef.ac.uk [last accessed 14 Oct 2008]
   Google Scholar